Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
26.10.2023 - AGAMREE Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential ... Seite 1
United States Patrickj Mcenany Drug Administration Catalyst Pharmaceuticals Santhera Pharmaceuticals Catalyst Or Company Nasdaq
Source: wallstreet-online.de